Neostigmine Treatment of Acute Pancreatitis Combined With Intra-abdominal

Status Completed

Clinical Trial Summary

Acute pancreatitis(A) often complicated with Intra-abdominal Hypertension. After the onset of acute pancreatitis, capillary leakage causing ascites,upper gastrointestinal tract obstruction and paralytic ileus leading to an elevated IAP, severe IAH leads to ACS with high mortality. Neostigmine is an anti-cholinesterase drugs, can enhance intestinal peristalsis, promote flatus defecation. The aim of this study was to determine the effect of neostigmine on reducing abdominal pressure and clinical prognosis in patients with AP by promoting intestinal peristalsis and defecation.

Clinical Trial Description

Acute pancreatitis(AP) runs a severe course in around 20% of patients and is associated with a mortality up to 30%. Intra-abdominal hypertension(IAH）is a common complication of severe acute pancreatitis(SAP). The inflammation of the pancreas starts a cascade of pancreatic and visceral edema, acute peripancreatic fluid collections, capillary leakage causing ascites, paralytic ileus, and gastric dilatation by upper gastrointestinal tract obstruction leading to an elevated intra-abdominal pressure (IAP). A sustained or repeated pathological elevation in IAP ≥12 mmHg is defined as IAH, it generally occurs often within the first week after onset of SAP. Persistent and serious IAH (IAP >20 mmHg ) often leads to new onset organ failure or acute worsening of existing organ failure, which is defined as ACS and associated with a mortality rate of 49%. In the past practice, many patients with ACS undergo decompressive laparotomy, which obviously has a risk of complications. Therefore, numerous medical, nonmedical, and minimally invasive therapies have been introduced. Neostigmine is an anti-cholinesterase drugs, can enhance intestinal peristalsis, promote flatus defecation. World Society for Abdominal Compartment Syndrome (WSACS)guidelines,suggest that neostigmine be used for the treatment of established colonic ileus not responding to other simple measures and associated with IAH.However, no data exist on the effects of pharmacologic promotility therapy on IAP or outcomes among those with IAH/ACS. The aim of this study was to evaluate the efficacy of neostigmine on reducing IAP in AP patients with IAH. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02543658
Study type	Interventional
Source	The First Affiliated Hospital of Nanchang University
Contact
Status	Completed
Phase	Phase 2
Start date	September 1, 2015
Completion date	May 30, 2018

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT05410795` - Establishment and Verification of Pancreatic Volume Formula Based on Imaging
Recruiting	`NCT04195347` - Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase	Phase 1/Phase 2
Completed	`NCT04735055` - Artificial Intelligence Prediction for the Severity of Acute Pancreatitis
Completed	`NCT02928718` - The Association Between Post-ERCP Acute Pancreatitis and Various Genetic Mutations
Terminated	`NCT02885441` - Treatment of Acute Pancreatitis With Ketorolac	Phase 4
Completed	`NCT02563080` - Pancreatic Exocrine Insufficiency in Acute Pancreatitis
Recruiting	`NCT01626911` - Continuous Regional Arterial Infusion of Low Molecular Weight Heparin in Patients With Severe Acute Pancreatitis	N/A
Completed	`NCT01507766` - The Correlations Between Early Enteral Nutrition and Intra-abdominal Pressure in Severe Acute Pancreatitis	Phase 4
Completed	`NCT04901949` - The Course of Acute Pancreatitis in Patients With Different BMI Groups
Recruiting	`NCT04814693` - Conventional Endoscopic Techniques Versus EndoRotor® System for Necrosectomy of Walled of Necrosis	N/A
Completed	`NCT02743364` - Simvastatin in Reducing Pancreatitis in Patients With Recurrent, Acute or Chronic Pancreatitis	Phase 2
Recruiting	`NCT05281458` - Early Versus Standard Endoscopic Interventions for Peripancreatic Fluid Collections	N/A
Not yet recruiting	`NCT04990336` - Dachaihu Decoction Compound and Rhubarb Single Medicine in the Treatment of Acute Pancreatitis	N/A
Not yet recruiting	`NCT03259880` - Searching the Best Prognostic Factor in Out Come Evaluation in Patients With Acute Pancreatitis Admitted at Assiut University Hospitals	N/A
Recruiting	`NCT06023771` - Invasive Intervention of Local Complications of Acute Pancreatitis
Not yet recruiting	`NCT05501314` - Remote Home Monitoring Acute Pancreatitis	N/A
Completed	`NCT02897206` - Imipenem Prophylaxis in Patients With Acute Pancreatitis	Phase 4
Recruiting	`NCT03634787` - Heat Shock Proteins: a Pathogenic Driver and Potential Therapeutic Target in Acute Pancreatitis
Active, not recruiting	`NCT04989166` - Effect of Nano-curcumin Supplementation in Acute Pancreatitis	N/A
Recruiting	`NCT05613673` - Prognostic Value of Different Nutritional Screening Tools in Acute Pancreatitis

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Neostigmine Treatment of Acute Pancreatitis Combined With Intra-abdominal Hypertension

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms